T1	PrimaryOutcome 62 130	efficacy of HCQ with respect to time to negative rRT-PCR assessments
T2	TimeFrame 131 163	from randomization up to 14 days
R1	MeasuredAt Arg1:T1 Arg2:T2	
T3	SecondaryOutcome 210 246	proportion of negative viral rRT-PCR
T4	TimeFrame 247 265	on hospital day 14
R2	MeasuredAt Arg1:T3 Arg2:T4	
T5	SecondaryOutcome 271 330	resolution of clinical symptoms (time to clinical recovery)
T6	SecondaryOutcome 336 360	proportion of discharges
T7	TimeFrame 361 370	by day 14
R3	MeasuredAt Arg1:T6 Arg2:T7	
T8	SecondaryOutcome 380 394	mortality rate
T9	OtherOutcome 396 423	HCQ safety and tolerability
